Targeted metabolomics reveals altered amino acid profiles in patients with coronary artery disease, suggesting potential biomarkers.
Purpose: This study aims to delineate the plasma amino acid profile in patients undergoing coronary angiography (CA) and identify potential biomarkers associated with Coronary artery disease (CAD). Materials and Methods: A targeted metabolomics approach was employed to analyze plasma levels of 41 amino acids in 25 CAD patients (pre- and post-CA) and 25 healthy controls. Plasma samples from patients pre- and post-CA, as well as from healthy controls, were analyzed using high-performance liquid chromatography tandem mass spectrometry (LC-MS/MS) to determine free amino acid profiles. Amino acid concentrations were quantified. Results: In pre-CA patients, levels of arginine (35.124±14.476 µmol/L), asparagine (34.386±6.41 µmol/L), aspartic acid (11.266±4.788 µmol/L), glutamic acid (136.502±54.193µmol/L), and branched-chain amino acids such as leucine (168.451±85.247µmol/L) and isoleucine (66.067±14.605 µmol/L) were markedly lower than in controls. Conversely, hydroxyproline (27.16±21.173 µmol/L), hydroxylysine (0.21±0.116µmol/L), cystine (27.039±11.978 µmol/L), and ethanolamine (13.136±5.812 µmol/L) were elevated. Post-CA, further reductions were observed in asparagine (30.408±7.121µmol/L), leucine (106.362±25.446 µmol/L), isoleucine (57.637±11.83 µmol/L), threonine (81.422±16.043 µmol/L), and tryptophan (36.548±12.014 µmol/L). Conclusion: These findings highlight the potential of amino acid profiling as a diagnostic and therapeutic tool for CAD, providing insights into disease pathogenesis and opportunities for targeted interventions.
No takes yet. Share an insight, caveat, or question.
Dikme et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: